[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=e7d9d75c37effd8b7e8b1d16c7a03e5f7f5c66410bee41915382bdff80bca687",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739205780,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "id": 132641110,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=e7d9d75c37effd8b7e8b1d16c7a03e5f7f5c66410bee41915382bdff80bca687"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s macular oedema therapy shows promise in Phase III trial",
    "summary": "In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.",
    "url": "https://finnhub.io/api/news?id=938a0134f860bba6a4d7fbb91d7d3842c4f6f947c79c88cdc5fb1e24baae14eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739204508,
      "headline": "Regeneron’s macular oedema therapy shows promise in Phase III trial",
      "id": 132819286,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2025/02/CTA-3-Regeneron-shutterstock_2148333613-1.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.",
      "url": "https://finnhub.io/api/news?id=938a0134f860bba6a4d7fbb91d7d3842c4f6f947c79c88cdc5fb1e24baae14eb"
    }
  },
  {
    "ts": null,
    "headline": "Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?",
    "summary": "Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.",
    "url": "https://finnhub.io/api/news?id=ca0d6c4c06f2ecff9cb2fe5eff01d3f52d5d49b02ffefac8031fa444e0d316f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739199300,
      "headline": "Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?",
      "id": 132635333,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.",
      "url": "https://finnhub.io/api/news?id=ca0d6c4c06f2ecff9cb2fe5eff01d3f52d5d49b02ffefac8031fa444e0d316f9"
    }
  },
  {
    "ts": null,
    "headline": "Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move",
    "summary": "Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover.  While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).  CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals.",
    "url": "https://finnhub.io/api/news?id=9b23cf8ee82cda98a382430d4fb49a419c19f9ed37e368ab695a6b96a2d1d034",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739186100,
      "headline": "Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move",
      "id": 132660381,
      "image": "https://g.foolcdn.com/editorial/images/806140/scientist-altering-dna-genome-project.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover.  While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).  CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals.",
      "url": "https://finnhub.io/api/news?id=9b23cf8ee82cda98a382430d4fb49a419c19f9ed37e368ab695a6b96a2d1d034"
    }
  }
]